Biocon Ltd expects its overall revenue to grow in mid-teens this financial year, and the company is betting on a robust launch pipeline in its generics as well as biosimilars businesses to drive ...

Pharma major Biocon says its businesses are at a promising inflection point, with strong momentum expected to continue. “We are at a stage where all our business segments are positioned for ...

Biocon remains bullish on its market share prospects in the US, supported by over 70 per cent market access with payers and healthcare providers, said Matthew Erick, Chief Commercial Officer ...

Biocon's stock saw a price increase of 2.11% to reach Rs 336.80 during today's trading session. This movement is significant as it reflects intraday dynamics and investor response to market ...

BENGALURU, India, April 28, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523) (NSE: BIOCON), today ...

Biocon Ltd has been approved by the board to raise up to ₹4,500 crore by issuing securities. The fundraising may be executed in one or more tranches using qualified institutional placements (QIP ...

Biocon Ltd. released its Q4 FY 25 results. The pharma major posted consolidated net profit of ₹344.5 crore in Q4FY25, down from ₹135.5 crore in the corresponding quarter last year. The ...

Biocon in its consolidated financial results for the fiscal fourth quarter registered Rs. 4,454 crore up by 15 per cent after adjusting FY24 revenue for BFI revenue, divestment gain and licensing ...